Harmony Biosciences Holdings Inc.is a pharmaceutical company. It engages in developing and commercializing therapies for rare neurological disorders. Harmony Biosciences Holdings Inc.is based in Plymouth Meeting, Pennsylvania.
| Revenue (Most Recent Fiscal Year) | $868.45M |
| Net Income (Most Recent Fiscal Year) | $158.69M |
| PE Ratio (Current Year Earnings Estimate) | 9.33 |
| PE Ratio (Trailing 12 Months) | 10.96 |
| PEG Ratio (Long Term Growth Estimate) | 0.35 |
| Price to Sales Ratio (Trailing 12 Months) | 1.97 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.80 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 10.41 |
| Pre-Tax Margin (Trailing 12 Months) | 23.55% |
| Net Margin (Trailing 12 Months) | 18.05% |
| Return on Equity (Trailing 12 Months) | 18.55% |
| Return on Assets (Trailing 12 Months) | 13.24% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.44 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.42 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.12 |
| Inventory Turnover (Trailing 12 Months) | 44.94 |
| Book Value per Share (Most Recent Fiscal Quarter) | $18.26 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.81 |
| Earnings per Share (Most Recent Fiscal Year) | $2.71 |
| Diluted Earnings per Share (Trailing 12 Months) | $3.02 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 58.72M |
| Free Float | 52.26M |
| Market Capitalization | $1.94B |
| Average Volume (Last 20 Days) | 1.17M |
| Beta (Past 60 Months) | 1.00 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.23% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |